WebMar 4, 2024 · AGN-151587 (EDIT-101) is a CRISPR-based experimental medicine under … WebJul 26, 2024 · Ms. Collins most recently served as the CEO of Editas Medicine, and prior to that served as the CEO of Human Longevity, Inc.; the CEO/GM of the Cell Therapy and Lab Business of General...
Editas Medicine Appoints Cynthia Collins as President and Chief ...
WebCollins was replaced in 2024 by James Mullen, who had been board chairman. Gilmore … WebJan 9, 2024 · Collins added, “I look forward to working with Michelle, Harry, and the rest of our strong executive team as progress through the clinical trial for EDIT-101, advance our pipeline, and execute on our bold vision to develop transformative, durable medicines for people living with serious diseases.” can dogs get on the bus
Editas Medicine Announces Fourth Quarter and Full Year 2024
WebCB Rank (Person) 999,792. Primary Job Title Lead Director. Primary Organization. Panavance Therapeutics. Location Cambridge, Massachusetts, United States. Regions Greater Boston Area, East Coast, New England. Gender Female. LinkedIn View on LinkedIn. Cynthia Collins is the Lead Director at Panavance Therapeutics Inc.. WebAug 6, 2024 · Cynthia Collins has been appointed president and CEO of Editas Medicine (NASDAQ: EDIT). Collins has been serving as interim CEO of the Cambridge, MA, company since Katrine Bosley left the chief ... WebMs. Collins has more than 40 years of leadership experience in cell and gene therapies … fishstick transparent